CHR 2797

Key Product Details

Product Description

CHR 2797 is an aminopeptidase inhibitor (IC₅₀ values are 100, 150, 220, > 1000, > 5000, > 10000 and > 30000 nM for LAP, PuSA, aminopeptidase N, aminopeptidase B, PILSAP, LTA₄ hydrolase and MetAP2, respectively). Potently inhibits tumor cell proliferation in a variety of tumor cell lines in vitro and in vivo. Also inhibits neprilysin (IC₅₀ = 900 nM). Exhibits antinociceptive activity and enhances the efficacy of Morphine (Cat. No. 5158) in the hot-plate and tail-flick assays, via an action on the peripheral nervous system.

Product Specifications for CHR 2797

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for CHR 2797

The following data is based on the product molecular weight 406.48.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

4 3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.46 mL	12.30 mL	24.60 mL
5 mM	0.49 mL	2.46 mL	4.92 mL
10 mM	0.25 mL	1.23 mL	2.46 mL
50 mM	0.05 mL	0.25 mL	0.49 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 6 publications citing the usage of this product.

• Moore Aminopeptidase inhibition as a targeted treatment strategy in myeloma. Mol.Cancer Ther. 2009 PMID: 19372548
• Singh Discovery of anticancer clinical candidate, Tosedostat, as an analgesic agent. ACS Chem.Neurosci. 2019 PMID: 31415151
• Krige CHR-2797: an anitproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res. 2008 PMID: 18701491

Product Documents for CHR 2797